{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:49:30Z","timestamp":1793371770701,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00051"],"award-info":[{"award-number":["75N93019C00051"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-68457-6","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T15:26:51Z","timestamp":1769182011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An H5N1 clade 2.3.4.4b virus vaccine that elicits cross-protective antibodies against conserved domains of H5 and N1 glycoproteins"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2816-7051","authenticated-orcid":false,"given":"Eduard","family":"Puente-Massaguer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thales","family":"Galdino Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Scherm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Vasilev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5433-6939","authenticated-orcid":false,"given":"Hassanein","family":"Abozeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alesandra J.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Yueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1564-3298","authenticated-orcid":false,"given":"Disha","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8526-3330","authenticated-orcid":false,"given":"John D.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4397-7132","authenticated-orcid":false,"given":"Richard J.","family":"Webby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5061-8296","authenticated-orcid":false,"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3402-2609","authenticated-orcid":false,"given":"Julianna","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-3769","authenticated-orcid":false,"given":"Andrew B.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-776X","authenticated-orcid":false,"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"68457_CR1","doi-asserted-by":"publisher","first-page":"e0220924","DOI":"10.1128\/jvi.02209-24","volume":"99","author":"F Krammer","year":"2025","unstructured":"Krammer, F., Hermann, E. & Rasmussen, A. L. Highly pathogenic avian influenza H5N1: history, current situation, and outlook. J. Virol. 99, e0220924 (2025).","journal-title":"J. Virol."},{"key":"68457_CR2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41586-024-08054-z","volume":"637","author":"TP Peacock","year":"2025","unstructured":"Peacock, T. P. et al. The global H5N1 influenza panzootic in mammals. Nature 637, 304\u2013313 (2025).","journal-title":"Nature"},{"key":"68457_CR3","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2213-2600(25)00052-9","volume":"13","author":"J Taaffe","year":"2025","unstructured":"Taaffe, J. et al. An overview of influenza H5 vaccines. Lancet Respir. Med. 13, e20\u2013e21 (2025).","journal-title":"Lancet Respir. Med."},{"key":"68457_CR4","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1038\/s41591-024-03189-y","volume":"30","author":"S Khurana","year":"2024","unstructured":"Khurana, S. et al. Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus. Nat. Med. 30, 2771\u20132776 (2024).","journal-title":"Nat. Med."},{"key":"68457_CR5","doi-asserted-by":"publisher","unstructured":"Liedes, O. et al. Inactivated zoonotic influenza A(H5N8) vaccine induces robust antibody responses against recent highly pathogenic avian influenza clade 2.3.4.4b A(H5N1) viruses. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2025.02.12.25322044 (2025).","DOI":"10.1101\/2025.02.12.25322044"},{"key":"68457_CR6","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1086\/652701","volume":"201","author":"JM Langley","year":"2010","unstructured":"Langley, J. M. et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1\/2 trial in adults. J. Infect. Dis. 201, 1644\u20131653 (2010).","journal-title":"J. Infect. Dis."},{"key":"68457_CR7","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","volume":"14","author":"EJ Ko","year":"2018","unstructured":"Ko, E. J. & Kang, S. M. Immunology and efficacy of MF59-adjuvanted vaccines. Hum. Vaccin. Immunother. 14, 3041\u20133045 (2018).","journal-title":"Hum. Vaccin. Immunother."},{"key":"68457_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2249130","volume":"12","author":"TT Tzeng","year":"2023","unstructured":"Tzeng, T. T. et al. A TLR9 agonist synergistically enhances protective immunity induced by an Alum-adjuvanted H7N9 inactivated whole-virion vaccine. Emerg. Microbes Infect. 12, 2249130 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"68457_CR9","doi-asserted-by":"publisher","first-page":"eadi4753","DOI":"10.1126\/sciadv.adi4753","volume":"9","author":"E Puente-Massaguer","year":"2023","unstructured":"Puente-Massaguer, E. et al. Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice. Sci. Adv. 9, eadi4753 (2023).","journal-title":"Sci. Adv."},{"key":"68457_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/14760584.2018.1516553","volume":"17","author":"F Sicca","year":"2018","unstructured":"Sicca, F., Neppelenbroek, S. & Huckriede, A. Effector mechanisms of influenza-specific antibodies: neutralization and beyond. Expert Rev. Vaccines 17, 785\u2013795 (2018).","journal-title":"Expert Rev. Vaccines"},{"key":"68457_CR11","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41577-024-01030-8","volume":"24","author":"TR Mosmann","year":"2024","unstructured":"Mosmann, T. R., McMichael, A. J., LeVert, A., McCauley, J. W. & Almond, J. W. Opportunities and challenges for T cell-based influenza vaccines. Nat. Rev. Immunol. 24, 736\u2013752 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"68457_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60714-4","volume":"16","author":"X Huang","year":"2025","unstructured":"Huang, X. et al. Increase in H5N1 vaccine antibodies confers cross-neutralization of highly pathogenic avian influenza H5N1. Nat. Commun. 16, 5517 (2025).","journal-title":"Nat. Commun."},{"key":"68457_CR13","doi-asserted-by":"publisher","first-page":"1097349","DOI":"10.3389\/fbioe.2023.1097349","volume":"11","author":"E Puente-Massaguer","year":"2023","unstructured":"Puente-Massaguer, E. et al. Bioprocess development for universal influenza vaccines based on inactivated split chimeric and mosaic hemagglutinin viruses. Front. Bioeng. Biotechnol. 11, 1097349 (2023).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"68457_CR14","doi-asserted-by":"publisher","first-page":"127671","DOI":"10.1016\/j.vaccine.2025.127671","volume":"64","author":"MJ Scherm","year":"2025","unstructured":"Scherm, M. J. et al. Assessment of critical bioprocess parameters for broadly cross-reactive chimeric hemagglutinin influenza virus vaccines. Vaccine 64, 127671 (2025).","journal-title":"Vaccine"},{"key":"68457_CR15","doi-asserted-by":"publisher","first-page":"110050","DOI":"10.1016\/j.virol.2024.110050","volume":"594","author":"X Zheng","year":"2024","unstructured":"Zheng, X. et al. Alum\/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity. Virology 594, 110050 (2024).","journal-title":"Virology"},{"key":"68457_CR16","doi-asserted-by":"crossref","unstructured":"Siegers, J. Y. et al. Resurgence of Zoonotic Highly Pathogenic Avian Influenza A(H5N1) Virus in Cambodia. N. Engl. J. Med. 393, 1650\u20131652 (2025).","DOI":"10.1056\/NEJMc2504302"},{"key":"68457_CR17","doi-asserted-by":"publisher","first-page":"126994","DOI":"10.1016\/j.vaccine.2025.126994","volume":"54","author":"F Krammer","year":"2025","unstructured":"Krammer, F. Next-generation seasonal influenza virus vaccines need a neuraminidase component. Vaccine 54, 126994 (2025).","journal-title":"Vaccine"},{"key":"68457_CR18","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.immuni.2023.07.004","volume":"56","author":"L Hansen","year":"2023","unstructured":"Hansen, L. et al. Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo. Immunity 56, 1927\u20131938 e1928 (2023).","journal-title":"Immunity"},{"key":"68457_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1172\/JCI84428","volume":"126","author":"DJ DiLillo","year":"2016","unstructured":"DiLillo, D. J., Palese, P., Wilson, P. C. & Ravetch, J. V. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Invest. 126, 605\u2013610 (2016).","journal-title":"J. Clin. Invest."},{"key":"68457_CR20","doi-asserted-by":"publisher","first-page":"e0347924","DOI":"10.1128\/mbio.03479-24","volume":"16","author":"J Sidney","year":"2025","unstructured":"Sidney, J. et al. Targets of influenza human T-cell response are mostly conserved in H5N1. mBio 16, e0347924 (2025).","journal-title":"mBio"},{"key":"68457_CR21","doi-asserted-by":"publisher","first-page":"e0398924","DOI":"10.1128\/mbio.03989-24","volume":"16","author":"E Hermann","year":"2025","unstructured":"Hermann, E. & Krammer, F. Clade 2.3.4.4b H5N1 neuraminidase has a long stalk, which is in contrast to most highly pathogenic H5N1 viruses circulating between 2002 and 2020. mBio 16, e0398924 (2025).","journal-title":"mBio"},{"key":"68457_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0076-2","volume":"3","author":"S Khurana","year":"2018","unstructured":"Khurana, S. et al. AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization. NPJ Vaccines 3, 40 (2018).","journal-title":"NPJ Vaccines"},{"key":"68457_CR23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.antiviral.2017.06.012","volume":"144","author":"SS Paul","year":"2017","unstructured":"Paul, S. S. et al. A cross-clade H5N1 influenza A virus neutralizing monoclonal antibody binds to a novel epitope within the vestigial esterase domain of hemagglutinin. Antivir. Res. 144, 299\u2013310 (2017).","journal-title":"Antivir. Res."},{"key":"68457_CR24","doi-asserted-by":"publisher","first-page":"12619","DOI":"10.1128\/JVI.01577-13","volume":"87","author":"X Zhu","year":"2013","unstructured":"Zhu, X. et al. A unique and conserved neutralization epitope in H5N1 influenza viruses identified by an antibody against the A\/Goose\/Guangdong\/1\/96 hemagglutinin. J. Virol. 87, 12619\u201312635 (2013).","journal-title":"J. Virol."},{"key":"68457_CR25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1126\/science.1171491","volume":"324","author":"DC Ekiert","year":"2009","unstructured":"Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246\u2013251 (2009).","journal-title":"Science"},{"key":"68457_CR26","doi-asserted-by":"crossref","unstructured":"Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343\u20131348 (2012).","DOI":"10.1126\/science.1222908"},{"key":"68457_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7114","volume":"6","author":"H Wan","year":"2015","unstructured":"Wan, H. et al. Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers. Nat. Commun. 6, 6114 (2015).","journal-title":"Nat. Commun."},{"key":"68457_CR28","doi-asserted-by":"publisher","first-page":"eads1273","DOI":"10.1126\/scitranslmed.ads1273","volume":"16","author":"M Hatta","year":"2024","unstructured":"Hatta, M. et al. An influenza mRNA vaccine protects ferrets from lethal infection with highly pathogenic avian influenza A(H5N1) virus. Sci. Transl. Med. 16, eads1273 (2024).","journal-title":"Sci. Transl. Med."},{"key":"68457_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48555-z","volume":"15","author":"C Furey","year":"2024","unstructured":"Furey, C. et al. Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus. Nat. Commun. 15, 4350 (2024).","journal-title":"Nat. Commun."},{"key":"68457_CR30","doi-asserted-by":"crossref","unstructured":"Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J. Vis. Exp. e51112 (2013).","DOI":"10.3791\/51112"},{"key":"68457_CR31","doi-asserted-by":"publisher","first-page":"e0203024","DOI":"10.1128\/mbio.02030-24","volume":"16","author":"AN Leon","year":"2025","unstructured":"Leon, A. N. et al. Structural mapping of polyclonal IgG responses to HA after influenza virus vaccination or infection. mBio 16, e0203024 (2025).","journal-title":"mBio"},{"key":"68457_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38415-7","volume":"14","author":"A Kandeil","year":"2023","unstructured":"Kandeil, A. et al. Rapid evolution of A(H5N1) influenza viruses after intercontinental spread to North America. Nat. Commun. 14, 3082 (2023).","journal-title":"Nat. Commun."},{"key":"68457_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1056\/NEJMc2405495","volume":"391","author":"L Guan","year":"2024","unstructured":"Guan, L. et al. Cow\u2019s milk containing avian influenza A(H5N1) virus - heat inactivation and infectivity in mice. N. Engl. J. Med. 391, 87\u201390 (2024).","journal-title":"N. Engl. J. Med."},{"key":"68457_CR34","doi-asserted-by":"publisher","first-page":"10580","DOI":"10.1128\/JVI.01213-08","volume":"82","author":"R Hai","year":"2008","unstructured":"Hai, R. et al. Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J. Virol. 82, 10580\u201310590 (2008).","journal-title":"J. Virol."},{"key":"68457_CR35","doi-asserted-by":"crossref","unstructured":"Rajendran, M. et al. An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations. PLoS ONE 13, e0194830 (2018).","DOI":"10.1371\/journal.pone.0194830"},{"key":"68457_CR36","doi-asserted-by":"crossref","unstructured":"Alzua, G. P. et al. Human monoclonal antibodies that target clade 2.3.4.4b H5N1 hemagglutinin. Nat. Commun. 17, 135 (2026).","DOI":"10.1038\/s41467-025-66829-y"},{"key":"68457_CR37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cell.2018.03.030","volume":"173","author":"YQ Chen","year":"2018","unstructured":"Chen, Y. Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417\u2013429 e410 (2018).","journal-title":"Cell"},{"key":"68457_CR38","doi-asserted-by":"publisher","first-page":"e02556","DOI":"10.1128\/mBio.02556-14","volume":"6","author":"TJ Wohlbold","year":"2015","unstructured":"Wohlbold, T. J. et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio 6, e02556 (2015).","journal-title":"mBio"},{"key":"68457_CR39","doi-asserted-by":"publisher","unstructured":"Zhu, Y. P. et al. Preparation of whole bone marrow for mass cytometry analysis of neutrophil-lineage cells. J. Vis. Exp. https:\/\/doi.org\/10.3791\/59617 (2019).","DOI":"10.3791\/59617"},{"key":"68457_CR40","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1128\/JVI.00137-12","volume":"86","author":"R Hai","year":"2012","unstructured":"Hai, R. et al. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J. Virol. 86, 5774\u20135781 (2012).","journal-title":"J. Virol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68457-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68457-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68457-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:04:09Z","timestamp":1771391049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68457-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68457"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68457-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Icahn School of Medicine at Mount Sinai has filed patent applications regarding influenza virus vaccines on which E.P.-M. and F.K. are listed as inventors. F.K. has consulted for Merck, GSK, Gritstone, Sanofi, Curevac, Seqirus, and Pfizer and is currently consulting for 3rd Rock Ventures and Avimex. The laboratory of F.K. is also collaborating with Dynavax on influenza vaccine development and with VIR on influenza virus therapeutics. A.B.W. has received royalty payments for the licensure of a prefusion coronavirus spike stabilization technology for which he is a co-inventor. A.B.W. and J.H. are currently consulting for Third Rock Ventures and Merida Biosciences. The laboratory of A.B.W. received unrelated sponsored research agreements from Third Rock Ventures during the conduct of the study. The authors declare that they have no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1749"}}